JS
Jason Scott Slakter
Chief Executive OfficerDirector

Jason Scott Slakter insider trades: Ohr Pharmaceutical (OHRP) stock purchases

Chief Executive Officer, Ohr Pharmaceutical Last trade Apr 10, 2017 17 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
11
Open-market trades
since 2015
1
Company
last trade 2017

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Jason reports to the SEC

Open-market buys and sales

11 trades reported on SEC Form 4, newest first

DateStockTypeValue
Apr 10, 2017OHRP↑ Buy$100K
Jun 20, 2016OHRP↑ Buy$25K
May 25, 2016OHRP↑ Buy$11K
May 24, 2016OHRP↑ Buy$88K
Apr 11, 2016OHRP↑ Buy$21K
Mar 7, 2016OHRP↑ Buy$23K
Feb 22, 2016OHRP↑ Buy$19K
Jan 19, 2016OHRP↑ Buy$23K
Dec 7, 2015OHRP↑ Buy$12K
Nov 3, 2015OHRP↑ Buy$40K
Feb 6, 2015OHRP↑ Buy$200K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Jason Scott Slakter's insider trades

Jason Scott Slakter is Chief Executive Officer at Ohr Pharmaceutical (OHRP). Since Feb 6, 2015, Jason has reported 11 open-market purchases worth $563K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include other transactions (4 filings), grants and awards (3 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every OHRP insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.